hydroxyzine
Adjunctive therapy • Brands: VISTARIL, ATARAX
Last reviewed: 2025-12-28
General information
- Class: Adjunctive therapy
- Common US brands: VISTARIL, ATARAX
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-28
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
First-generation antihistamine (H1 antagonist) with sedating and anxiolytic effects; anticholinergic/antiemetic properties.
Metabolism & Half‑life
- Metabolism: Hepatic
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Hydroxyzine hydrochloride prescribing information — DailyMed (2025)
- Hydroxyzine pamoate prescribing information — DailyMed (2025)
- Evidence-based pharmacological treatment of anxiety disorders — Depression and Anxiety (2014)
- New restrictions to minimise the risks of effects on heart rhythm with hydroxyzine-containing medicines — European Medicines Agency (2015)
- Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care — International Journal of Psychiatry in Clinical Practice (2012)